Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Radotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 12/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 11/20 | 0.83 |
| ▸ | LDLR | P01130 | 8/20 | 0.83 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.83 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.83 |
| ▸ | LCK | P06239 | 4/20 | 0.83 |
| ▸ | LYN | P07948 | 4/20 | 0.83 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.83 |
| ▸ | FLT3 | P36888 | 4/20 | 0.83 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.83 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.83 |
| ▸ | SRC | P12931 | 2/20 | 0.83 |
| ▸ | RAF1 | P04049 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radotinib SCHEMBL29381661 | 1.00 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL3359952 | 1.00 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL30002961 | 0.99 | ABL1 (0.99) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL15285797 | 0.99 | ABL1 (0.99) | ABL1BCRADORA3NR1I2PTGS1 | |
| Radotinib SCHEMBL15318848 | 0.99 | ABL1 (0.97) | ABL1BCRADORA3NR1I2PTGS1 | |
| SCHEMBL3945090 | 0.92 | ABL1 (0.85) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL29366964 | 0.91 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL29580067 | 0.91 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| Nilotinib SCHEMBL7901 | 0.91 | ABL1 (1.00) | ABL1BCRADORA3NR1I2PTGS1 | |
| SCHEMBL20502603 | 0.91 | KIT (0.85) | ABL1BCRADORA3NR1I2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| WO-2025245128-A1 | ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | MYTHIC THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4638443-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | claimed |
| EP-4630456-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF | Mythic Therapeutics, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250288520-A1 | Microemulsion Pharmaceutical Composition For Treatment Of Disorders Of The Anterior Segment Of The Eye | SIFI S.P.A. (IT) | 2025-09-18 | — | — | US | claimed |
| EP-4601621-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | Nanotech Pharma Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4074317-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | Bayer AG (DE) | 2022-10-19 | — | — | EP | claimed |
| EP-4038054-A1 | PYRIMIDINEDIONE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2022-08-10 | — | — | EP | claimed |
| US-20220241261-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-04 | — | — | US | claimed |
| EP-3426657-B1 | 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES | Bayer Pharma AG (DE) | 2022-07-13 | — | — | EP | claimed |
| WO-2022104097-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| EP-3288558-B1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | Bayer Pharma AG (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-3982930-A1 | MICROEMULSION COMPOSITIONS | SIFI S.p.A. (IT) | 2022-04-20 | — | — | EP | claimed |
| EP-3373932-B1 | CRYSTALLINE FORM OF A SUBSTITUTED QUINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-03-30 | — | — | EP | claimed |
| CN-111302997-B | Method for preparing Raatinib intermediate by one-pot method | 江苏恒沛药物科技有限公司 | 2022-03-29 | — | — | CN | claimed |
| US-20220025036-A1 | USE OF IL-1BETA BINDING ANTIBODIES | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | SGMS2, SGMS1, LIPA | ABL1 3198/4885BCR 171/4885ADORA3 4005/4885 |
| US-20220241261-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | IRAK4, IRAK2, IRAK1 | ABL1 3100/4885BCR 1149/4885ADORA3 4539/4885 |
| US-20220025036-A1 | USE OF IL-1BETA BINDING ANTIBODIES | IL1B, IL1RN, IL1A | ABL1 464/4885BCR 59/4885ADORA3 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.